As the United Arab Emirates (UAE) continues to position itself as a leader in innovation, a pivotal development occurred on April 12, 2026, when Sheikh Khaled bin Mohamed bin Zayed Al Nahyan arrived in Beijing. This visit underscores the UAE’s commitment to fostering international collaboration and advancing its technological landscape.
Central to this initiative is the newly established R&D tax credit regime, operationalized under Ministerial Decision No. 24 of 2026. This regime, which follows the Cabinet Decision No. 215 of 2025, offers a generous tax credit of up to 50% on qualifying expenditures, designed to stimulate research and development across various sectors.
The credit operates on a tiered structure, providing different rates based on the amount of qualifying expenditure. For instance, expenditures of 1 million AED qualify for a 15% credit, while those reaching 5 million AED can benefit from the full 50% rate. This tiered approach is expected to encourage businesses to invest significantly in R&D.
Moreover, the UAE has emerged as a regional reference and training hub for advanced ultrasound applications, particularly in the context of the 3D ultrasound market. This market is transitioning from a high-end niche to a procedural standard, driven by clinical demand for volumetric quantification in prenatal cardiology and image-guided interventions.
The installed base refresh cycle for ultrasound technology is also accelerating, largely due to software-driven obsolescence. This trend indicates a growing need for continuous investment in cutting-edge technology, which the new R&D tax credit aims to facilitate.
However, the implementation of this tax credit is not without its complexities. The UAE R&D tax credit makes transfer pricing (TP) compliance a condition precedent to credit qualification, meaning that companies must adhere to specific regulations to benefit from these incentives. The dual-threshold design of the credit has direct TP implications, as it prevents companies from satisfying headcount requirements through intra-group secondments.
As the UAE forges ahead with these initiatives, the implications for businesses and the healthcare sector are profound. The R&D tax credit not only incentivizes innovation but also positions the UAE as a competitive player in the global market for advanced medical technologies.
In summary, the recent developments surrounding the R&D tax credit and Sheikh Khaled’s visit to Beijing mark a significant step for the UAE in its quest for economic diversification and technological advancement. The outcomes of these initiatives will be closely watched as they unfold in the coming months.
